LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TGX221 | 10.0 | uM | LJP5 | 1 | H19 | 72 | hr | 1657 | 5792 | 5505 | 1.0520 | 1.0744 |
| BT-20 | TGX221 | 10.0 | uM | LJP5 | 2 | H19 | 72 | hr | 1657 | 6079 | 5505 | 1.1041 | 1.1490 |
| BT-20 | TGX221 | 10.0 | uM | LJP5 | 3 | H19 | 72 | hr | 1657 | 6070 | 5505 | 1.1025 | 1.1467 |
| BT-20 | Torin1 | 10.0 | uM | LJP6 | 1 | O13 | 72 | hr | 1657 | 879 | 5505 | 0.1597 | -0.2024 |
| BT-20 | Torin1 | 10.0 | uM | LJP6 | 2 | O13 | 72 | hr | 1657 | 1047 | 5505 | 0.1902 | -0.1587 |
| BT-20 | Torin1 | 10.0 | uM | LJP6 | 3 | O13 | 72 | hr | 1657 | 1315 | 5505 | 0.2388 | -0.0891 |
| BT-20 | Torin2 | 10.0 | uM | LJP5 | 1 | I19 | 72 | hr | 1657 | 1027 | 5505 | 0.1865 | -0.1639 |
| BT-20 | Torin2 | 10.0 | uM | LJP5 | 2 | I19 | 72 | hr | 1657 | 1316 | 5505 | 0.2390 | -0.0888 |
| BT-20 | Torin2 | 10.0 | uM | LJP5 | 3 | I19 | 72 | hr | 1657 | 1384 | 5505 | 0.2514 | -0.0711 |
| BT-20 | Tozasertib | 10.0 | uM | LJP5 | 1 | B13 | 72 | hr | 1657 | 1696 | 5505 | 0.3081 | 0.0099 |
| BT-20 | Tozasertib | 10.0 | uM | LJP5 | 2 | B13 | 72 | hr | 1657 | 1625 | 5505 | 0.2952 | -0.0085 |
| BT-20 | Tozasertib | 10.0 | uM | LJP5 | 3 | B13 | 72 | hr | 1657 | 1660 | 5505 | 0.3015 | 0.0006 |
| BT-20 | Trametinib | 10.0 | uM | LJP5 | 1 | P19 | 72 | hr | 1657 | 4236 | 5505 | 0.7694 | 0.6700 |
| BT-20 | Trametinib | 10.0 | uM | LJP5 | 2 | P19 | 72 | hr | 1657 | 4409 | 5505 | 0.8008 | 0.7150 |
| BT-20 | Trametinib | 10.0 | uM | LJP5 | 3 | P19 | 72 | hr | 1657 | 4384 | 5505 | 0.7963 | 0.7085 |
| BT-20 | TWS119 | 10.0 | uM | LJP5 | 1 | M01 | 72 | hr | 1657 | 1934 | 5505 | 0.3513 | 0.0718 |
| BT-20 | TWS119 | 10.0 | uM | LJP5 | 2 | M01 | 72 | hr | 1657 | 1992 | 5505 | 0.3618 | 0.0869 |
| BT-20 | TWS119 | 10.0 | uM | LJP5 | 3 | M01 | 72 | hr | 1657 | 1874 | 5505 | 0.3404 | 0.0562 |
| BT-20 | Vemurafenib | 10.0 | uM | LJP5 | 1 | C13 | 72 | hr | 1657 | 3676 | 5505 | 0.6677 | 0.5245 |
| BT-20 | Vemurafenib | 10.0 | uM | LJP5 | 2 | C13 | 72 | hr | 1657 | 3646 | 5505 | 0.6622 | 0.5167 |
| BT-20 | Vemurafenib | 10.0 | uM | LJP5 | 3 | C13 | 72 | hr | 1657 | 4222 | 5505 | 0.7669 | 0.6664 |
| BT-20 | Withaferin A | 10.0 | uM | LJP5 | 1 | G13 | 72 | hr | 1657 | 886 | 5505 | 0.1609 | -0.2006 |
| BT-20 | Withaferin A | 10.0 | uM | LJP5 | 2 | G13 | 72 | hr | 1657 | 908 | 5505 | 0.1649 | -0.1948 |
| BT-20 | Withaferin A | 10.0 | uM | LJP5 | 3 | G13 | 72 | hr | 1657 | 1006 | 5505 | 0.1827 | -0.1694 |
| BT-20 | Withaferin A | 10.0 | uM | LJP6 | 1 | G13 | 72 | hr | 1657 | 716 | 5505 | 0.1301 | -0.2447 |